INTRODUCTION
. This is reflected in the significant improvement in 5-year relative survival rate in the USA from 25% in 1975-1977 to 49% in 2005-2011 [2] . Virtually all MM patients ultimately relapse or become refractory after first-or second-line therapy [5] and these patients represent a clinical challenge because of their poor clinical outcome [6] . Alternative immunomodulatory drugs (pomalidomide) [7] and proteasome inhibitors (carfilzomib, ixazomib) [8, 9] , new agents such as the histone deacetylase inhibitor panobinostat [10] , and novel monoclonal antibodies (mAbs) directed at different targets such as CD38 (daratumumab) [11] and SLAMF7 (elotuzumab) [12] have been approved more recently for treatment of relapsed/refractory MM. Novel agents that act through different mechanisms are still needed and are under investigation [13] .
Gangliosides are ubiquitous cell membrane components composed of a carbohydrate chain with sialic acid at the cell surface and a hydrophobic ceramide in the lipid bilayers [14] . Some of these gangliosides play a role in cell-cell recognition [15] and cell-matrix attachment [16] that regulate cell growth and differentiation [17, 18] . Quantitative and qualitative changes are known to occur in the expression of gangliosides through the oncogenic transformation of cells [15] , so attention has been directed to gangliosides as therapeutic targets [19, 20] . The recognition of potential immunologic differences between cancer cells and normal cells led to an immunotherapy trial in an attempt to immunize metastatic melanoma patients against the GM2 ganglioside [21] . GM2 ganglioside is expressed in a range of other tumor cell types, e.g. neuroblastoma, leukemia, and it was noted that the majority of myeloma cell lines (70%) and myeloma cells in patient marrow specimens (64%) expressed GM2 ganglioside on the cell surface [22] .
BIW-8962 is a recombinant, humanized, non-fucosylated immunoglobulin G1 mAb directed against the GM2 ganglioside.
BIW-8962 was produced in Chinese Hamster Ovary (CHO) cells that lack the FUT8 gene, rendering the mAb devoid of fucose in the carbohydrate structure. Non-fucosylated mAbs have been shown to have up to 100-fold higher antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells compared to conventional fucosylated antibodies [23] .
Preclinical studies employed a precursor mAb, KM8969, with the same complementarity-determining regions as BIW-8962. The binding activity of KM8969
was assessed with an enzyme-linked immunoassay using various immobilized gangliosides as previously reported [24] .
KM8969 reacted strongly with N-acetyl-GM2 and N-glycolyl-GM2 but weakly with GD2.
In vitro preclinical studies (data on file, Kyowa The aim of the current first-in-human phase I study was to determine the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, potential immunogenicity, and preliminary clinical efficacy of BIW-8962 administered by iv infusion as monotherapy in patients with previously treated multiple myeloma.
METHODS

Study Design
The primary phase I objective was to establish the safety profile and recommended phase II dose as determined by either the MTD or the active biologic dose (ABD) of BIW-8962 in patients with previously treated MM.
Secondary objectives were to determine the pharmacokinetic profile of BIW-8962, to evaluate preliminary evidence of antitumor activity, and to screen for potential antibodies against BIW-8962.
As this was the first-in-class human study of BIW-8962, the starting dose level was based on a 12-week toxicology study in cynomolgus monkeys (data on file, Kyowa Kirin Development, Inc.), which showed the no observed adverse effect level was 0.1 mg/kg administered weekly. The selected human starting dose of BIW-8962 0.03 mg/kg iv once every 2 weeks provided a safety factor of six with the dosing regimen difference factored in, which is sufficiently high for relapsed MM patients.
The study had a multi-center, open-label design consisting of three sequential parts: dose escalation to determine the MTD or ABD (phase Ia) followed by dosing regimen determination using adjustment with a loading dose (phase Ib) followed by an efficacy assessment (phase II). Phases Ib and II were not conducted due to lack of preliminary efficacy in phase Ia and, as such, 
Safety and Clinical Assessment
Demographic and medical/cancer histories were recorded at screening. Bone marrow aspiration and biopsy were performed during screening.
Physical examination and laboratory value assessments were undertaken at screening, on 
Statistics
Safety, efficacy, and pharmacokinetics were summarized by descriptive statistics.
Compliance with Ethical Guidelines
The study was conducted in accordance with the Declaration of Helsinki and International The study was registered in ClinicalTrials.gov (NCT00775502). All patients provided written informed consent prior to study registration.
RESULTS
Patient Characteristics
The study is complete and was conducted between Table 2 . The safety and efficacy populations included 23 and 22 patients, respectively. The reasons for discontinuation from the study were progressive disease (n = 22, 95.7%) and AEs (n = 1, 4.3%).
Dose-Limiting Toxicity
Two patients developed DLTs: one at 0.03 mg/ kg and one at 1 mg/kg. The number of evaluable patients was therefore increased to six in each of these cohorts. Seven patients eventually entered the 0.03 mg/kg cohort as one patient received only one dose and discontinued study medication due to disease progression, which necessitated replacement. No additional patients developed DLT. The DLT in the 0.03 mg/kg cohort was grade 3 atrial thrombosis and cardiomyopathy possibly related to the study drug. The DLT in the 1 mg/kg cohort was grade 3 chest pain probably related to the study drug. The latter patient died during the study but this was not considered drug-related (see next section). Both DLTs led to discontinuation of study drug.
Neither the MTD nor the ABD was reached. No patients were recruited to the highest planned dose level of 10 mg/kg prior to discontinuation of the trial.
Safety
AEs are summarized in Table 3 . Treatment-related AEs occurred in 8 (34.8%) patients, did not appear related to dose, and, by preferred term, were reported in individual patients except for alopecia (n = 2). There were no treatment-related life-threatening AEs or deaths. Treatment-related grade 3 AEs were reported in two patients (atrial thrombosis ? cardiomyopathy in one patient and chest pain in the other): these were the DLTs reported above. The patient who experienced grade 3 chest pain probably related to BIW-8962 occurred after receiving a partial dose of study drug (1 mg/kg cohort) on day 1 in the context of a grade 2 infusion reaction: the patient died on day 6 due to cardiopulmonary arrest that was considered unrelated to the study drug. The patient who experienced grade 3 atrial thrombosis and cardiomyopathy had a medical history of congestive heart failure with pre-existing cardiomyopathy. Both these DLTs were classed as SAEs. One other patient experienced a treatment-related SAE: this involved a patient who received 3 mg/kg and experienced grade 3 fatigue plus a grade 2 infusion reaction, which were considered probably and definitely related to study drug, respectively. All other SAEs were not considered related to the study drug and were generally typical of the underlying disease process, e.g. hypercalcemia, plasmacytoma, infection, fracture.
No unexpected trends or safety concerns were identified from laboratory parameter, vital sign, or ECG assessments. Anti-BIW-8962
antibodies were not detected in plasma for any patients except one who developed a weakly positive response.
Anti-Tumor Activity
No patient had a complete or partial response, with no patient showing a C50% reduction in serum M protein and a C90% reduction in 24-h urinary M protein or to \200 mg/24 h. Sixteen Median time to disease progression was 6.7 (range 2.1-34.1) weeks (Table 2) . Single-agent treatment with elotuzumab showed no objective clinical responses in a phase I study in heavily pretreated MM patients [25] . Given that lenalidomide and bortezomib enhanced the activity of elotuzumab in preclinical models, further clinical studies were conducted of elotuzumab in combination lenalidomide [26, 27] and bortezomib [28, 29] that demonstrated additive or synergistic activities 
